VEGFA and neoplasm: It is reasonable to postulate that bevacizumab’s ability to block the activity of dermal vessel vascular endothelial growth factor may have resulted in sufficient vascular damage to result in anoxia and subsequent lysis of the metastatic tumor cells in the dermis and the prompt development of skin ulcers where the cutaneous metastases had previously been located.